Clinical Trials Directory

Trials / Completed

CompletedNCT03521700

Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement

A Prospective, Randomized Trial to Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Although expert consensuses recommend the use of statins in the treatment of atherosclerotic renal artery stenosis, in patients with severe atherosclerotic renal artery stenosis undergoing stent placement, the related investigation focused on renal protection by intensive lipid-lowering therapy is scant , and the optimal target level for lipid reduction remain uncertain. Therefore, we hypothesized that intensive lipid lowering could offer more benefits with respect to renal function in the patients with percutaneous renal artery stenting. We conducted the prospective randomized unblinded trial to compare the renal-protective effect of intensive lipid lowering with that of conventional lipid lowering in patients underwent renal artery stenting (75 patients in each study group)

Conditions

Interventions

TypeNameDescription
DRUGRosuvastatinFor patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.

Timeline

Start date
2013-06-01
Primary completion
2014-12-30
Completion
2015-12-30
First posted
2018-05-11
Last updated
2018-05-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03521700. Inclusion in this directory is not an endorsement.